Such data encourage exploring the role of Schlafens in various subtypes of cancer rather than aggregating all types of cancer in a given organ or tissue together and suggests SLFN5 and SLFN12 as potential therapeutic targets for breast cancer. This evidence concerns the gene SLFN12 and breast cancer.